Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) Enterprise Value (2016 - 2025)

Haemonetics has reported Enterprise Value over the past 17 years, most recently at -$363.4 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$363.4 million for Q4 2025, down 13.25% from a year ago — trailing twelve months through Dec 2025 was -$363.4 million (down 13.25% YoY), and the annual figure for FY2025 was -$306.8 million, down 71.57%.
  • Enterprise Value for Q4 2025 was -$363.4 million at Haemonetics, down from -$296.4 million in the prior quarter.
  • Over the last five years, Enterprise Value for HAE hit a ceiling of -$173.5 million in Q3 2021 and a floor of -$363.4 million in Q4 2025.
  • Median Enterprise Value over the past 5 years was -$272.0 million (2022), compared with a mean of -$262.6 million.
  • Biggest five-year swings in Enterprise Value: skyrocketed 37.15% in 2024 and later crashed 71.57% in 2025.
  • Haemonetics' Enterprise Value stood at -$192.4 million in 2021, then decreased by 16.41% to -$224.0 million in 2022, then grew by 13.4% to -$194.0 million in 2023, then plummeted by 65.4% to -$320.8 million in 2024, then dropped by 13.25% to -$363.4 million in 2025.
  • The last three reported values for Enterprise Value were -$363.4 million (Q4 2025), -$296.4 million (Q3 2025), and -$292.9 million (Q2 2025) per Business Quant data.